Medicare Enrolled
Dr. William McGarry, M.D.
Hematology & Oncology · Vero Beach, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. McGarry from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. McGarry? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. McGarry
Dr. William McGarry is a hematology & oncology in Vero Beach, FL, with 20 years in practice. Based on federal Medicare data, Dr. McGarry performed 190,338 Medicare services across 6,911 unique beneficiaries.
Between the years covered by Open Payments, Dr. McGarry received a total of $8,908 from 64 pharmaceutical and/or device companies across 415 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McGarry is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 2% volume in FL$ $8,908 industry payments
Medicare Practice Summary
Medicare Utilization ↗190,338
Medicare services
Top 2% in FL for hematology & oncology
6,911
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,517 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 48,450 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 22,600 | $43 | $137 |
| Nivolumab injection (Opdivo) | 18,840 | $24 | $72 |
| Anti-nausea injection (aprepitant) | 15,340 | $1 | $5 |
| Oxaliplatin chemotherapy injection | 14,442 | $0 | $12 |
| Paclitaxel chemotherapy injection | 9,858 | $0 | $2 |
| Daratumumab injection (Darzalex) | 7,200 | $38 | $110 |
| Denosumab injection (Prolia/Xgeva) | 6,420 | $19 | $51 |
| Epoetin alfa injection (Procrit) for anemia | 6,230 | $6 | $23 |
| Iron sucrose injection (Venofer) | 4,400 | $0 | $5 |
| Complete blood count (CBC) with differential | 3,315 | $8 | $29 |
| Dexamethasone injection (steroid) | 3,201 | $0 | $3 |
| Injection, eflapegrastim-xnst, 0.1 mg | 3,036 | $25 | $116 |
| Blood draw (venipuncture) | 3,024 | $8 | $9 |
| Epoetin alfa injection (Retacrit) for anemia | 2,950 | $6 | $22 |
| Immune globulin infusion (Gammagard) | 2,602 | $36 | $108 |
| Office visit, established patient (30-39 min) | 2,139 | $100 | $339 |
| Contrast dye for imaging (iodine-based) | 1,820 | $0 | $1 |
| Iron infusion (Monoferric) | 1,800 | $17 | $57 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,580 | $1 | $28 |
| Injection, atropine sulfate, 0.01 mg | 1,440 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,355 | $23 | $185 |
| Anti-nausea injection (ondansetron/Zofran) | 848 | $0 | $9 |
| Injection, leucovorin calcium, per 50 mg | 840 | $3 | $12 |
| Drug injection, under skin or into muscle | 775 | $11 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 594 | $106 | $378 |
| Injection of additional new drug or substance into vein | 556 | $13 | $61 |
| Injection, fluorouracil, 500 mg | 475 | $2 | $7 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 355 | $3 | $205 |
| Red blood count, automated test | 295 | $4 | $10 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 265 | $24 | $84 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 265 | $1 | $6 |
| Injection, carboplatin, 50 mg | 254 | $2 | $41 |
| Administration of chemotherapy into vein, each additional hour | 252 | $23 | $79 |
| Injection, diphenhydramine hcl, up to 50 mg | 243 | $1 | $3 |
| New patient office visit (45-59 min) | 204 | $135 | $453 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 197 | $52 | $189 |
| Injection, cisplatin, powder or solution, 10 mg | 177 | $2 | $13 |
| Administration of additional new drug or substance into vein, 1 hour or less | 149 | $52 | $178 |
| Office visit, established patient (20-29 min) | 144 | $70 | $239 |
| Infusion, normal saline solution , 1000 cc | 104 | $2 | $7 |
| Injection, zoledronic acid, 1 mg | 103 | $7 | $69 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 97 | $59 | $206 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 97 | $26 | $89 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 95 | $17 | $56 |
| Hospital follow-up visit, high complexity | 84 | $99 | $285 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 78 | $134 | $562 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 76 | $19 | $59 |
| Injection of drug or substance into vein | 74 | $29 | $156 |
| Infusion into a vein for hydration, 31-60 minutes | 59 | $27 | $156 |
| Hospital follow-up visit, low complexity | 58 | $42 | $109 |
| Hospital follow-up visit, moderate complexity | 58 | $64 | $197 |
| Infusion into a vein for hydration, each additional hour | 56 | $11 | $42 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 51 | $143 | $637 |
| Administration of additional new drug or substance into vein using push technique | 50 | $46 | $170 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 47 | $4 | $15 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 45 | $16 | $56 |
| Drawing of blood for a medical problem | 44 | $73 | $277 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 44 | $1 | $7 |
| Automated urinalysis | 42 | $2 | $8 |
| Ct scan of abdomen and pelvis before and after contrast | 20 | $211 | $708 |
| Initial hospital admission, high complexity | 15 | $133 | $556 |
| New patient office visit (30-44 min) | 11 | $89 | $298 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
28.2% high complexity
66.6% medium
5.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$8,908
Total received (2018-2024)
Avg $1,273/year across 7 years
Top 38% in FL for hematology & oncology
64
Companies
415
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,858 (99.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$51 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,036
2023$3,148
2022$940
2021$319
2020$29
2019$96
2018$339
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$799
Novartis Pharmaceuticals Corporation
$745
Merck Sharp & Dohme LLC
$735
Celgene Corporation
$583
PFIZER INC.
$404
ABBVIE INC.
$327
Incyte Corporation
$304
GlaxoSmithKline, LLC.
$280
Janssen Biotech, Inc.
$256
E.R. Squibb & Sons, L.L.C.
$256
Myriad Genetic Laboratories, Inc.
$244
Seagen Inc.
$230
Axonics, Inc.
$230
Takeda Pharmaceuticals U.S.A., Inc.
$204
Eisai Inc.
$200
Ipsen Biopharmaceuticals, Inc
$190
Lilly USA, LLC
$186
Amgen Inc.
$145
BeiGene USA, Inc.
$145
ARRAY BIOPHARMA INC
$126
Gilead Sciences, Inc.
$125
Regeneron Healthcare Solutions, Inc.
$122
Astellas Pharma US Inc
$119
Genentech USA, Inc.
$107
Kite Pharma, Inc.
$104
Pharmacyclics LLC, An AbbVie Company
$101
Daiichi Sankyo Inc.
$101
GENZYME CORPORATION
$92
Bayer Healthcare Pharmaceuticals Inc.
$92
Mirati Therapeutics, Inc.
$91
Bayer HealthCare Pharmaceuticals Inc.
$89
Pharmacosmos Therapeutics Inc.
$80
Alexion Pharmaceuticals, Inc.
$78
TerSera Therapeutics LLC
$71
Stemline Therapeutics Inc.
$64
JAZZ PHARMACEUTICALS INC.
$49
ADC Therapeutics America, Inc.
$46
Pharmacyclics LLC, an AbbVie Company
$46
Biocon Biologics Inc
$46
Merck Sharp & Dohme Corporation
$45
Exelixis Inc.
$42
Deciphera Pharmaceuticals Inc.
$41
Kyowa Kirin, Inc.
$39
Sumitomo Pharma America, Inc.
$39
Blueprint Medicines Corporation
$37
AbbVie Inc.
$37
Karyopharm Therapeutics Inc.
$35
Agios Pharmaceuticals, Inc.
$32
AVEO Pharmaceuticals, Inc.
$30
SOBI, INC
$29
PharmaEssentia USA Corporation
$26
Dendreon Pharmaceuticals LLC
$26
SERVIER PHARMACEUTICALS LLC
$25
EISAI INC.
$24
CTI BioPharma Corp.
$23
Sun Pharmaceutical Industries Inc.
$21
Alnylam Pharmaceuticals Inc.
$21
EMD Serono, Inc.
$20
Aveo Pharmaceuticals, Inc.
$20
NOVARTIS PHARMACEUTICALS CORPORATION
$18
TAIHO ONCOLOGY, INC.
$16
SpringWorks Therapeutics, Inc.
$16
RECORDATI_RARE_DISEASES_INC.
$15
Progenics Pharmaceuticals, Inc.
$15
Top 3 companies account for 25.6% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AUGTYRO · AYVAKIT · Axonics · BESREMI · BLENREP · BOSULIF · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CARVYKTI · COSELA · CYRAMZA · Columvi · DARZALEX · DOPTELET · ELAHERE · ELIQUIS · ELZONRIS · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · FOTIVDA · FRUZAQLA · Fabhalta · Fulphila · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JADENU · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUPRON DEPOT · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NINLARO · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONPATTRO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ogivri · Onivyde · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYLARIFY · PYRUKYND · Pomalyst · Poteligeo · QINLOCK · REBLOZYL · RETEVMO · Revlimid · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · SYLVANT · Somatuline Depot · TASIGNA · TECVAYLI · TIVDAK · TUKYSA · Tecentriq · Tibsovo · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONVENDI · VOTRIENT · Venclexta · Vonjo · Vyloy · XALKORI · XPOVIO · XTANDI · Xofigo · Xospata · YONSA · Yescarta · ZEJULA · ZEPZELCA · Zoladex · Zydelig
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
19
Per 100K population
11.6
County median income
$71,049
Nearest hospital
CLEVELAND CLINIC INDIAN RIVER HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. McGarry is a mixed practice specialist, with above-average Medicare volume (top 2% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. McGarry experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. McGarry performed 48,450 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. McGarry receive payments from pharmaceutical companies?
Yes. Dr. McGarry received a total of $8,908 from 64 companies across 415 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. McGarry's costs compare to other hematology & oncologys in Vero Beach?
Dr. McGarry's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. McGarry) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Vero Beach
Browse hematology & oncologys in Vero Beach ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in FL
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in FL
Which FL hematology & oncologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology